Literature DB >> 3876858

T-cell subsets in multiple myeloma. Impact of cytostatic treatment.

A Wahlin, G Roos, J Holm.   

Abstract

Blood leukocyte and lymphocyte counts, absolute and relative numbers of T-lymphocytes and T-cell subsets were studied in 45 patients with multiple myeloma and 18 healthy controls. No differences were found between untreated patients and controls. In the group of untreated patients similar results were obtained in patients with low-intermediate tumour cell mass as in patients with large tumour cell mass. In patients with large tumour cell mass studied during cytostatic therapy, leukocyte and lymphocyte counts, T-cells, OKT4+ cells and OKT4/OKT8 ratios were significantly lower than in untreated patients. Patients studied at varying intervals (2-28 mo.) after cessation of therapy still exhibited abnormal leukocyte and lymphocyte counts, numbers of T-cells, OKT4+ cells and OKT4/OKT8 ratios.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876858     DOI: 10.1007/bf00320524

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  9 in total

Review 1.  Immunoregulation of murine myeloma cell growth and differentiation: a monoclonal model of B cell differentiation.

Authors:  R G Lynch; J W Rohrer; B Odermatt; H M Gebel; J R Autry; R G Hoover
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  Abnormal nucleic acid metabolism of lymphocytes in plasma cell myeloma and macroglobulinemia.

Authors:  S E Salmon; H H Fudenberg
Journal:  Blood       Date:  1969-02       Impact factor: 22.113

3.  T-cell imbalances in patients with multiple myeloma: an analysis by monoclonal antibodies.

Authors:  C D Platsoucas; H J Hansen; J R Redman; S Berenson; B J Lee; B D Clarkson
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

Review 4.  Occurrence and potential significance of increased numbers of T cells with Fc receptors in myeloma.

Authors:  R G Hoover; H M Gebel; B K Dieckgraefe; S Hickman; N F Rebbe; N Hirayama; Z Ovary; R G Lynch
Journal:  Immunol Rev       Date:  1981       Impact factor: 12.988

5.  Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.

Authors:  D C Case; D J Lee; B D Clarkson
Journal:  Am J Med       Date:  1977-12       Impact factor: 4.965

6.  Lymphocyte transformation in patients with paraproteinaemia.

Authors:  A E Campbell; J De Vine; L Azam; J Hamid; I W Delamore; H McFarlane
Journal:  Br J Haematol       Date:  1975-01       Impact factor: 6.998

7.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

8.  Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage.

Authors:  K H Mills; J C Cawley
Journal:  Br J Haematol       Date:  1983-02       Impact factor: 6.998

9.  T cells in monoclonal gammopathies.

Authors:  H Mellstedt; G Holm; D Pettersson; M Björkholm; B Johansson; C Lindemalm; D Peest; A Ahre
Journal:  Scand J Haematol       Date:  1982-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.